Thanthima Suwanthawornkul1, Thunyarat Anothaisintawee2*, Abhasnee Sobhonslidsuk3, Ammarin Thakkinstian4, Yot Teerawattananon1 1 Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand, 2 Department of Family Medicine, Faculty of Medicine, Ramathibodi

Full text: http://link.springer.com/article/10.1007s40273-015-0360-1

Kittiphong Thiboonboon1 , Benjarin Santatiwongchai1 ,Varit Chantarastapornchit1 , Waranya Rattanavipapong1 , Yot Teerawattananon1 Abstract Background For more than three decades, the number and influence of economic evaluations of healthcare interventions have been increasing and gaining atte

Abstract BACKGROUND: Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis

Abstract Objectives This study aims to assess the value for money and budget impact of offering hemodialysis (HD) as a first-line treatment, or the HD-first policy, and the peritoneal dialysis (PD) first policy compared to a supportive care option in patients with end-stage renal disease (ESRD)

The use of economic evaluation in healthcare policies and decision-making, which is limited in low- and middle-income countries (LMICs), might be promoted through the improvement of the conduct and reporting of studies. Although the literature indicates that there are many issues affecting the condu

Primary care serves as an entry point in the Thai health care system. Whilst effective interventions are provided in the primary care setting, the quality of the services have not been measured or tracked. A number of initiatives were undertaken to improve primary health care quality including the u

SUMMARY POINTS •  End stage renal disease (ESRD) is a life-threatening condition that results in most patients requiring a lifetime of high cost renal dialysis •  Governments have grappled with the political, economic, and ethical challenges of providing treatment with their available budgets •

Public policy for kidney replacement therapy eludes most low- and middle-income countries owing to the seemingly low number of cases and high cost. Countries such as Thailand have shown that public health authorities can effectively provide treatment and elevate health care for populations by overco

Abstract As COVID-19 ravages the world, many countries are faced with the grim reality of not having enough critical-care resources to go around. Knowing what could be in store, the Thai Ministry of Public Health called for the creation of an explicit protocol to determine how these resources are